Logo image of ORIC

ORIC PHARMACEUTICALS INC (ORIC) Stock Price, Quote, News and Overview

NASDAQ:ORIC - Nasdaq - US68622P1093 - Common Stock - Currency: USD

8.17  +0.2 (+2.51%)

After market: 8.21 +0.04 (+0.49%)

ORIC Quote, Performance and Key Statistics

ORIC PHARMACEUTICALS INC

NASDAQ:ORIC (5/30/2025, 8:24:39 PM)

After market: 8.21 +0.04 (+0.49%)

8.17

+0.2 (+2.51%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High14.67
52 Week Low3.9
Market Cap580.81M
Shares71.09M
Float62.18M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-11 2025-08-11
IPO04-24 2020-04-24


ORIC short term performance overview.The bars show the price performance of ORIC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60

ORIC long term performance overview.The bars show the price performance of ORIC in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 100

The current stock price of ORIC is 8.17 USD. In the past month the price increased by 46.68%. In the past year, price decreased by -9.12%.

ORIC PHARMACEUTICALS INC / ORIC Daily stock chart

ORIC Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.12 328.74B
AMGN AMGEN INC 13.88 154.96B
GILD GILEAD SCIENCES INC 14.22 136.93B
VRTX VERTEX PHARMACEUTICALS INC N/A 113.52B
REGN REGENERON PHARMACEUTICALS 11.06 52.94B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 39.71B
ARGX ARGENX SE - ADR 97.66 35.00B
ONC BEONE MEDICINES LTD-ADR 6.28 26.55B
BNTX BIONTECH SE-ADR N/A 23.03B
NTRA NATERA INC N/A 21.54B
BIIB BIOGEN INC 8.2 19.02B
UTHR UNITED THERAPEUTICS CORP 12.72 14.38B

About ORIC

Company Profile

ORIC logo image Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. The company is headquartered in South San Francisco, California and currently employs 115 full-time employees. The company went IPO on 2020-04-24. The firm is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The firm's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.

Company Info

ORIC PHARMACEUTICALS INC

240 E. Grand Ave, 2nd Floor

South San Francisco CALIFORNIA 94080 US

CEO: Jacob M. Chacko

Employees: 115

ORIC Company Website

ORIC Investor Relations

Phone: 16503885600

ORIC PHARMACEUTICALS INC / ORIC FAQ

What is the stock price of ORIC PHARMACEUTICALS INC today?

The current stock price of ORIC is 8.17 USD. The price increased by 2.51% in the last trading session.


What is the ticker symbol for ORIC PHARMACEUTICALS INC stock?

The exchange symbol of ORIC PHARMACEUTICALS INC is ORIC and it is listed on the Nasdaq exchange.


On which exchange is ORIC stock listed?

ORIC stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ORIC PHARMACEUTICALS INC stock?

18 analysts have analysed ORIC and the average price target is 18.36 USD. This implies a price increase of 124.72% is expected in the next year compared to the current price of 8.17. Check the ORIC PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ORIC PHARMACEUTICALS INC worth?

ORIC PHARMACEUTICALS INC (ORIC) has a market capitalization of 580.81M USD. This makes ORIC a Small Cap stock.


How many employees does ORIC PHARMACEUTICALS INC have?

ORIC PHARMACEUTICALS INC (ORIC) currently has 115 employees.


What are the support and resistance levels for ORIC PHARMACEUTICALS INC (ORIC) stock?

ORIC PHARMACEUTICALS INC (ORIC) has a support level at 4.89 and a resistance level at 8.18. Check the full technical report for a detailed analysis of ORIC support and resistance levels.


Should I buy ORIC PHARMACEUTICALS INC (ORIC) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ORIC PHARMACEUTICALS INC (ORIC) stock pay dividends?

ORIC does not pay a dividend.


When does ORIC PHARMACEUTICALS INC (ORIC) report earnings?

ORIC PHARMACEUTICALS INC (ORIC) will report earnings on 2025-08-11.


What is the Price/Earnings (PE) ratio of ORIC PHARMACEUTICALS INC (ORIC)?

ORIC PHARMACEUTICALS INC (ORIC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.87).


What is the Short Interest ratio of ORIC PHARMACEUTICALS INC (ORIC) stock?

The outstanding short interest for ORIC PHARMACEUTICALS INC (ORIC) is 18.52% of its float. Check the ownership tab for more information on the ORIC short interest.


ORIC Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to ORIC. When comparing the yearly performance of all stocks, ORIC is a bad performer in the overall market: 61.93% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ORIC Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ORIC. No worries on liquidiy or solvency for ORIC as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ORIC Financial Highlights

Over the last trailing twelve months ORIC reported a non-GAAP Earnings per Share(EPS) of -1.87. The EPS decreased by -3.89% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -46.64%
ROE -52.59%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-13.51%
Sales Q2Q%N/A
EPS 1Y (TTM)-3.89%
Revenue 1Y (TTM)N/A

ORIC Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 88% to ORIC. The Buy consensus is the average rating of analysts ratings from 18 analysts.


Ownership
Inst Owners98.89%
Ins Owners1.91%
Short Float %18.52%
Short Ratio15.17
Analysts
Analysts87.78
Price Target18.36 (124.72%)
EPS Next Y-2.5%
Revenue Next YearN/A